Juniper Pharma Services (JPS), a Nottingham, England-based contract development and Manufacturing Organisation (CDMO) specializing in the development of challenging small molecules, said it is “significantly” expanding its UK-based drug development and clinical trial manufacturing facilities.

The extension, planned to be completed this summer, will provide four additional process development laboratories at Nottingham that the company said will improve output and efficiency of its development and clinical manufacturing operations.

JPS said the new labs will enable it to work with an ever-growing client base to transform poorly soluble and difficult to formulate molecules into successful products. It said the expansion will also ensure that processing and formulation work is scalable, thus facilitating the efficient manufacture of stability and clinical batches.

Nikin Patel, president of Juniper Pharma Services, said the company continues to explore opportunities to extend its service offerings to meet the evolving requirements of its market and clients.